[ad_1]
CEO Dave Marver discusses the use of the company’s brain-computer interface technology and progress toward commercialization of ARC-EX®, expected later this year.
Eindhoven, Netherlands, February 7, 2024 (Globe Newswire) — ONWARD Medical NV (Euronext: ONWD) is developing an innovative spinal cord stimulation therapy to restore movement, function and independence to people with spinal cord injuries. (SCI), a medical technology company developing , today announced its participation in BioCapital Europe on February 8, 2024 in Amsterdam. The event is one of Europe’s leading life sciences investor conferences and is hosted by life sciences venture capital fund EQT Life Sciences, an investor in ONWARD Medical.
ONWARD Medical CEO Dave Marver will attend and participate in one-on-one and group meetings with investors during the conference. He will also discuss the company’s leadership in innovative health solutions, including the use of ONWARD ARC-IM® Therapy combined with brain-computer interface (BCI) technology.
*everything is moving forward medicine Devices and treatments including but not limited to ARC-IM®, Arc EX®ARC therapy™Either alone or in combination with a brain-computer interface (BCI), it is in the research stage and is not available for commercial use.
About Onward Medical
ONWARD Medical is a medical technology company that develops treatments to restore movement, function, and independence to people with spinal cord injuries (SCI) and movement disorders. Based on his more than 10 years of scientific and preclinical research conducted at leading neuroscience laboratories, the company received nine of his breakthrough device awards from the U.S. Food and Drug Administration for the ARC Therapy™ platform. has been designated.
ONWARD® ARC Therapy can be delivered by an external ARC-EX or implantable ARC-IM system and is designed to provide targeted and programmed spinal cord stimulation. Positive results were announced in 2023 from the company’s pivotal study, called Up-LIFT, evaluating the ability of transdermal ARC therapy to improve upper extremity strength and function. The Company is currently preparing regulatory filings for ARC-EX in the United States and Europe. In parallel, the company is conducting studies with its implantable ARC-IM platform, which demonstrated positive interim clinical outcomes regarding improved blood pressure regulation, a component of hemodynamic instability following SCI. Other ongoing research includes his combination of ARC-IM and brain-computer interfaces (BCI) to address multiple symptoms of SCI.
Headquartered in Eindhoven, Netherlands, ONWARD Medical has a science and engineering center in Lausanne, Switzerland, and a U.S. office in Boston, Massachusetts. The company also has an academic partnership with .NeuroRestore, a collaboration between the Swiss Federal Institute of Technology (EPFL) and the Lausanne University Hospital (CHUV).
ONWARD Medical is listed on Euronext Brussels and Amsterdam (ticker: ONWD).
For more information, visit ONWD.com and connect with us on LinkedIn and YouTube.
Media inquiries:
Aditi Roy, Vice President of Communications
media@onwd.com
Investor inquiries:
Khaled Bahi, Interim CFO
investor@onwd.com
Disclaimer
Certain statements, beliefs and opinions in this press release are forward-looking and reflect the current expectations and projections of future events of the Company or, as appropriate, of the Company’s directors. By their nature, forward-looking statements involve a number of risks, uncertainties and assumptions that could cause actual results or events to differ materially from those expressed or implied by the forward-looking statements. There is a possibility. These risks, uncertainties and assumptions may adversely affect the results and financial impact of the plans and events described herein. Numerous factors, including changes in demand, competition and technology, could cause actual events, performance and results to differ materially from anticipated developments. Any forward-looking statements contained in this press release regarding past trends or activities should not be construed as a representation that such trends or activities will continue in the future. As a result, the Company expressly disclaims any obligation or undertaking to release any updates or revisions to any forward-looking statements in this press release whether as a result of changes in expectations or as a result of changes in events, conditions, assumptions or circumstances. To do. These forward-looking statements are based on. Neither the Company nor any of its advisors or representatives, nor any of its subsidiaries or their officers or employees, provides any warranty that the assumptions underlying such forward-looking statements will be error-free; No responsibility is assumed for the future accuracy of. Actual events of statements contained in this press release or anticipated developments; You should not place undue reliance on forward-looking statements, which speak only as of the date of this press release. All ONWARD medical devices and therapies referenced herein, including but not limited to ARC-IM, ARC-EX, and ARC Therapy, are investigational and not available for commercial use.
[ad_2]
Source link
